Application-specific R&D capabilities and the advantage of incumbents: Evidence from the anticancer drug market

Management Science

Volumn 55, Issue 8, 2009, Pages 1409-1422

  Sosa, M Lourdes ^a  

^a LONDON BUSINESS SCHOOL   (United Kingdom)

Author keywords

Competence destruction; Incumbent; Market specificity; R D; Technological change

Indexed keywords

ANTICANCER DRUG; APPLICATION-SPECIFIC; BIOTECHNOLOGY REVOLUTION; COMPETENCE DESTRUCTION; COMPETITIVE ADVANTAGE; COMPLEMENTARY ASSETS; DRUG DISCOVERY; IN-PHASE; INCUMBENT; MARKET LEADERSHIP; MARKET SPECIFICITY; NEW TECHNOLOGIES; RESEARCH AND DEVELOPMENT; STRATEGIC FACTORS; TECHNOLOGICAL CHANGE; TECHNOLOGICAL DISCONTINUITIES; TECHNOLOGICAL PLATFORM;

COMPETITION; FIRE TUBE BOILERS; RESEARCH;

COMMERCE;

EID: 69049120449     PISSN: 00251909     EISSN: 15265501     Source Type: Journal    
DOI: 10.1287/mnsc.1090.1027     Document Type: Article

References (54)

1. References American Cancer Society. 2000. Cancer facts & figures. Accessed March 10, 2008, http://www.cancer.org/downloads/STT/F&F00.pdf.
2. Amit, R., P. J. H. Schoemaker. 1993. Strategic assets and organizational rent. Strategic Management J. 14(1) 33-46.
3. Ayala, F. A. 2006. Combustion lean limits fundamentals and their application to a SI hydrogen-enhanced engine concept. Unpublished doctoral dissertation, Massachusetts Institute of Technology, Cambridge.
4. Azoulay, P. 2004. Capturing knowledge within and across firm boundaries: Evidence from clinical development. Amer. Econom. Rev. 94(5) 1591-1612.
5. Barney, J. B. 1991. Firm resources and sustained competitive advantage. J. Management 17(1) 99-120.
6. Bear Sterns. 2002. Biotechnology: Cancer-Concepts and controversies, Volume 1. Report, Bear Sterns, New York.
7. Capdeville, R., E. Buchdunger, J. Zimmermann, A. Matter. 2002. Glivec (STI571, Imanitib), a rationally developed, targeted anticancer drug. Nature Rev. Drug Discovery 1 493-502.
8. Carroll, G. R., L. S. Bigelow, M. D. L. Seidel, L. B. Tsai. 1996. The Fates of de novo and de alio producers in the american automobile industry 1885-1981. Strategic Management J. 17(Special Issue) 117-137.
9. Chabner, B. A., T. G. Roberts, Jr. 2005. Timeline: Chemotherapy and the war on cancer. Nature Rev. Cancer 5 65-72.
10. Christensen, C. 1997. The Innovator's Dilemma. Harvard Business School Press, Boston.
11. Conner, K. R. 1988. Strategies for product cannibalism. Strategic Management J. 9(Special Issue) 9-26.
12. Cooper, A. C., D. Schendel. 1976. Strategic responses to technological threats. Bus. Horizons 19(1) 61-69.
13. Dierickx, I., K. Cool. 1989. Assets accumulation and sustainability of competition advantage. Management Sci. 35(12) 1504-1514.
14. Graham, S. J. H., M. J. Higgins. 2007. The impact of patenting on new product introductions in the pharmaceutical industry. Working paper, Georgia Institute of Technology, Atlanta.
15. Guedj, I., D. Scharfstein. 2004. Organizational scope and investment: Evidence from the drug development strategies and performance of biopharmaceutical firms. NBER Working Paper 10933, National Bureau of Economic Research, Cambrige, MA.
16. Helfat, C. E. 1997. Know-how and asset complementarity and dynamic capability accumulation: The case of R&D. Strategic Management J. 18(5) 339-360.
17. Henderson, R. M. 1993. Underinvestment and incompetence as responses to radical innovation-Evidence from the photolithographic alignment equipment industry. RAND J. Econom. 24(2) 248-270.
18. Henderson, R. M. 1995. Of life-cycles real and imaginary-The unexpectedly long old-age of optical lithography. Res. Policy 24(4) 631-643.
19. Henderson, R. M., K. B. Clark. 1990. Architectural innovation: The reconfiguration of existing product technologies and the failure of established firms. Admin. Sci. Quart. 35(1) 9-30.
20. Henderson, R. M., L. Orsenigo, G. Pisano. 1999. The pharmaceutical industry and the revolution in molecular biology: Interactions among scientific, institutional, and organizational change. D. C. Mowery, R. R. Nelson, eds. Sources of Industrial Leadership. Cambridge University Press, Cambridge, UK, 267-311.
21. International Business Machines (IBM). History of IBM. Accessed November 4, 2005, http://www-03.ibm.com/ibm/history/history/history-intro.html.
22. Klepper, S., K. L. Simons. 2000. Dominance by birthright: Entry of prior radio producers and competitive ramifications in the US television receiver industry. Strategic Management J. 21(10/11) 997-1016.
23. Lederman, M. 1981. The early history of radiotherapy: 1895-1939. Internat. J. Radiation Oncology, Biol., Phys. 7(5) 639-648.
24. Lu, Z. J., W. S. Comanor. 1998. Strategic pricing of new pharmaceuticals. Rev. Econom. Statist. 80(1) 108-118.
25. Maddala, G. S. 1983. Limited Dependent and Qualitative Variables in Econometrics. Cambridge University Press, Cambridge, UK.
26. Makadok, R. 2001. Toward a synthesis of the resource-based and dynamic-capability views of rent creation. Strategic Management J. 22 387-401.
27. Methe, D., A. Swaminathan, W. Mitchell. 1996. The underemphasized role of established firms as the sources of major innovations. Indust. Corporate Change 5(4) 1181-1203.
28. Mitchell, W. 1994. The dynamics of evolving markets: The effects of business sales and age on dissolutions and divestitures. Admin. Sci. Quart. 39(4) 575-602.
29. Montgomery, C. A., S. Hariharan. 1991. Diversified expansion by large established firms. J. Econom. Behav. Organ. 15 71-89.
30. Montgomery, C. A., B. Wernerfelt. 1988. Diversification, ricardian rents, and Tobin's Q. RAND J. Econom. 19(4) 623-632.
31. Nature. 2007. Nature milestones: DNA technologies. Accessed April 24, 2009, http://www.nature.com/milestones/miledna/timeline.html.
32. Nature Reviews Cancer. 2006. Nature milestones: Cancer. Accessed April 24, 2009, http://www.nature.com/milestones/milecancer/timeline.html.
33. Orsenigo, L. 1989. The Emergence of Biotechnology: Institutions and Markets in Industrial Innovation. Pinter Publishers, London.
34. Papke, L. E., J. Wooldridge. 1996. Econometric methods for fractional response variables with an application to 401(k) plan participation rates. J. Appl. Econometrics 11 619-632.
35. Rang, H. P. 2006. The drug discovery process: General principles and some case histories. H. P. Rang, ed. Drug Discovery and Development: Technology in Transition. Churchill Livingstone, London, 43-56.
36. Roberts, T. G., Jr., B. H. Goulart, L. Squitieri, S. C. Stallings, E. F. Halpern, B. A. Chabner, G. S. Gazelle, S. N. Finkelstein, J. W. Clark. 2004. Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials. J. Amer. Medical Assoc. 292(17) 2130-2140.
37. Rothaermel, F. T. 2001. Incumbent's advantage through exploiting complementary assets via interfirm cooperation. Strategic Management J. 22(6/7) 687-699.
38. Rumelt, R. P. 1982. Diversification strategy and profitability. Strategic Management J. 3 359-369.
39. Schumpeter, J. A. 1934. The Theory of Economic Development. Harvard University Press, Cambridge, MA.
40. Schumpeter, J. A. 1950. Capitalism, Socialism and Democracy, 3rd ed. Harper, New York.
41. Shepart, C. R., J. Kassis, D. L. Whaley, H. G. Kim, A. Wells. 2007. PLC gamma contributes to metastasis of in situ-occurring mammary and prostate tumors. Oncogene 26(21) 3020-3026.
42. Sigelman, L., L. Zeng. 1999. Analyzing censored and sampleselected data with tobit and heckit models. Political Anal. 8(2) 167-182.
43. Silverman, B. S. 1999. Technological resources and the direction of corporate diversification: Toward an integration of the resource-based view and transaction cost economics. Management Sci. 45(8) 1109-1124.
44. Sosa, M. L. 2006. Decoupling market incumbency from organizational experience: A study of biotechnology's impact on the market for anti-cancer drugs. Unpublished doctoral dissertation, Massachusetts Institute of Technology, Cambridge, MA.
45. Stephens Inc. 2002. Cancer, Revolutionary Therapies, Innovative Investment Opportunities, 2nd ed. Stephens Inc., Little Rock, AR.
46. Teece, D. J. 1986. Profiting from technological innovation: Implications for integration, collaboration, licensing and public policy. Res. Policy 15 285-305.
47. Teece, D. J., G. Pisano, A. Shuen. 1997. Dynamic capabilities and strategic management. Strategic Management J. 18(7) 509-533.
48. Tripsas, M. 1997. Unraveling the process of creative destruction: Complementary assets and incumbent survival in the typesetter industry. Strategic Management J. 18 119-142.
49. Tushman, M., P. Anderson. 1986. Technological discontinuities and organizational environments. Admin. Sci. Quart. 31(3) 439-465.
50. UBS Warburg. 2001. The Cancer Matrix: Exploring the Future of Cancer Therapy. UBS Warburg, Zurich.
51. Utterback, J. M. 1994. Mastering the Dynamics of Innovation. Harvard Business School Press, Boston.
52. Weinberg, R. A. 1996. Racing to the Beginning of the Road: The Search for the Origin of Cancer. W. H. Freeman and Company, New York.
53. Winter, S. G. 2003. Understanding dynamic capabilities. Strategic Management J. 24 991-995.
54. Zubrod, C. G. 1979. Historic milestones in curative chemotherapy. Seminars in Oncology 6(4) 490-505.